Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
treatment was similar to the reported findings in ischemic heart disease and data from other countries. This difference does not seem to be related only to “competing risk”. It is likely that patients reduced their physical activity during the state of alarm and, therefore, their probability of experiencing symptoms. In addition, those with mild symptoms were less likely to seek medical assessment. This could explain the lower pacemaker implantation rate in asymptomatic and presyncope patients. The disruption of ambulatory activity may also have limited the possibility to attain a prompt diagnosis in patients with mild conduction disorders, which could explain the relative increase in implants for cAVB. These findings should be taken into account in future COVID-19 waves to improve organization during crises by maintaining essential outpatient activity and fostering public confidence that all areas of the health system are safe against contagion.

Acknowledgements

The coordinators of this study express their sincere gratitude to the researchers who collaborated by collecting and sending data from their respective centers: Francisco de Asís Díaz Cortegana, Javier García Seara, Julia Martínez Solé, Pablo Ávila Alonso, Luis Borrego Bernabé, José María González Rebollo, Ernesto Díaz Infante, Óscar Alcalde Rodríguez, Josep Navarro Manchón, Francisco Javier García Fernández, José Manuel Rubio Campal, Luis Álvarez Acosta, María del Carmen Expósito Pineda, Rosa Macías-Ruiz, Pilar Cabanas Grandio, Rubén Juárez Prera, Miguel Angel Arias, Pablo Morriña Vázquez, Tomás Ripoll-Vera, Marta Pombo Jiménez, Fernando Cabestrero de Diego, Diego Lorente Carreño, Vicente Bertomeu González, Rafael Raso Raso, Pau Alonso Fernández and Jorge Toquero Ramos.

Ricardo Salgado Aranda, a,b Nicasio Pérez Castellano, a,b Óscar Cano Pérez, c Andrés Ignacio Bodegas Cañas, d Manuel Frutos López, a and Julián Pérez-Villacastín Domínguez a,b

aUnidad de Arritmias, Instituto Cardiovascular, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain
bCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
cUnidad de Electrofisiología, Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
dUnidad de Electrofisiología, Servicio de Cardiología, Hospital Universitario de Cruces, Baracaldo, Vizcaya, Spain

eUnidad de Arritmias, Servicio de Cardiología, Hospital Virgen del Rocío, Sevilla, Spain

*Corresponding author:
E-mail address: ricardosalgadodoc@gmail.com (R. Salgado Aranda).

Available online 30 November 2020

REFERENCES

1. Rodríguez-Leor O, Cid-Álvarez B, Ojeda S, et al. Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiología intervencionista en España. REC Interv Cardiol. 2020;2:82–89.
2. Toniolo M, Negri F, Antonutti M, Masé M, Facchin D. Unpredictable fall of severe emergent cardiovascular diseases hospital admissions during the COVID-19 pandemic: experience of a single large center in Northern Italy. J Am Heart Assoc. 2020. https://doi.org/10.1161/jaha.120.017122.
3. Migliore F, Zocchi A, Gregori D, et al. Urgent Pacemaker implantation rates in the Veneto region of Italy after the COVID-19 outbreak. Circ Arrhythm Electrophysiol. 2020;13:e008722.
4. Rodríguez-Padial L, Arias Mibau. El riesgo competitivo puede explicar en gran medida la disminución de los ingresos por enfermedad cardiovascular aguda durante la pandemia de COVID-19. Rev Esp Cardiol. 2020;73:1084–1085.

https://doi.org/10.1016/j.rec.2020.10.015
1885-5857/ © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
multivariate analyses adjusted for theoretical confounders (age, sex, body mass index, coronary heart disease, chronotropic treatment, chronic obstructive pulmonary disease, left ventricular ejection fraction ≤ 50%, and positive ESE result).

The total study sample consisted of 180 patients, 64 in the COVID-19 era (facemask group) and 116 in the pre-COVID-19 group (control group). Within the total sample, 74 (41.11%) were women, 53 (29.44%) had previous coronary artery disease, 13 (7.22%) had left ventricular systolic dysfunction, and the mean age was 63.54 years (standard deviation, 11.04). The baseline characteristics of the sample distributed by groups are summarized in Table 1. We found no differences between the 2 groups in the analyzed variables, except for a nonsignificant trend toward a higher body mass index in the control group.

The data on hemodynamic parameters, workload and ESE results are shown in Table 2. The main reason for stopping the test in both groups was muscle fatigue (75.00% facemask, 62.93% control, \( P = .09 \)). The workload reached was very similar in both groups (8.77 MET facemask, 8.76 MET control, \( P = .984 \)). Compared with patients with the control group, patients in the facemask group had significantly higher peak systolic blood pressure (181.81 mmHg vs 173.77 mmHg; \( P = .041 \)) and double product (26 640 vs 24 621; \( P = .019 \)). We obtained a higher percentage of conclusive studies in the facemask group (85.94% vs 65.52%; \( P = .003 \)). In the multivariate analysis, the use of the mask maintained a significant positive association with the percentage of conclusive studies (odds ratio, 3.95, 95% confidence interval, 1.52-10.25, \( P = .005 \)), and was not associated with the MET achieved (beta –0.25, 95% confidence interval, –0.84 to 0.35, \( P = .411 \)).

Previous studies have shown that heart rate during exercise is increased by the use of surgical facemasks in healthy participants. This may partly explain the higher percentage of conclusive studies obtained. The main weakness of our study is the impossibility of using the same patients without a facemask as their own control.

### Table 1
Baseline characteristics of the patients

|                           | Control group (without facemask) n = 116 | COVID-19 era group (with facemask) n = 64 | \( \text{P} \) |
|---------------------------|------------------------------------------|------------------------------------------|-------------|
| Female sex                | 46 (39.66)                               | 28 (43.75)                               | .593        |
| Age                       | 63.65 ± 11.65                            | 63.34 ± 9.92                             | .861        |
| BMI, kg/m\(^2\)           | 28.32 ± 3.75                             | 27.32 ± 3.75                             | .090        |
| COPD                      | 11 (9.48)                                | 5 (7.81)                                 | .706        |
| Coronary artery disease   | 36 (31.03)                               | 17 (26.56)                               | .529        |
| LVEF ≤ 50%                | 10 (8.62)                                | 3 (4.69)                                 | .386        |
| Chronotropic drug         | 42 (36.21)                               | 18 (28.12)                               | .271        |
| Beta-blocker              | 40 (95.24)                               | 15 (83.33)                               |             |
| Calcium channel blocker   | 1 (2.38)                                 | 2 (11.11)                                |             |
| Inderal                   | 1 (2.38)                                 | 1 (5.56)                                 |             |
| Inpatient                 | 27 (23.28)                               | 17 (26.56)                               | .623        |
| Appropriate indication    | 87 (75.00)                               | 54 (84.38)                               | .144        |
| Predicted MET             | 7.65 ± 1.92                              | 7.61 ± 1.74                              | .897        |
| Resting heart rate        | 77.79 ± 12.89                            | 80.48 ± 16.15                            | .223        |
| Resting systolic blood pressure | 133.29 ± 19.02 | 132.73 ± 17.60 | .847        |
| Heart rate reserve        | 78.56 ± 15.35                            | 76.17 ± 17.30                            | .341        |

BMI, body mass index; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MET, metabolic equivalents; Heart rate reserve, age predicted maximum heart rate - resting heart rate.

Data are expressed as No. (%) or mean ± standard deviation.

### Table 2
Data on hemodynamic, workload and test results

|                           | Control group (without facemask) n = 116 | COVID-19 era group (with facemask) n = 64 | \( \text{P} \) |
|---------------------------|------------------------------------------|------------------------------------------|-------------|
| Positive ESE              | 19 (16.38)                               | 9 (14.06)                                | .681        |
| Peak systolic blood pressure, mmHg | 173.77 ± 25.82 | 181.81 ± 23.69 | .041*       |
| Peak heart rate, bpm      | 140.72 ± 22.32                           | 146.84 ± 19.04                           | .065        |
| Double product            | 24 621.34 ± 6011.60                      | 26 640.14 ± 4066.74                      | .019*       |
| MET                       | 8.76 ± 2.88                              | 8.77 ± 2.69                              | .984        |
| MET reached – MET predicted | 1.12 ± 2.31                         | 1.16 ± 2.27                              | .898        |
| Patients reaching predicted MET | 86 (74.14)                  | 44 (68.75)                               | .440        |
| Conclusive study          | 76 (65.52)                               | 55 (85.94)                               | .003*       |

ESE, exercise stress echocardiogram; MET, metabolic equivalents; Double product, peak systolic blood pressure x peak heart rate.

Data are expressed as No. (%) or mean ± standard deviation.

* \( P < .05 \).
group, given the risk of aerosolization during ESE in the current pandemic situation. Given the retrospective nature of the analysis, it has not been possible to incorporate other variables related to chronotropic response, such as the level of sedentariness. However, this bias was mitigated by the use of body mass index as a surrogate variable. Finally, we cannot exclude a possible causal role of physical deconditioning, caused by confinement, on the maximum heart rate achieved.

In conclusion, our study demonstrates that ESE with a surgical facemask is a feasible procedure. The use of a facemask does not negatively affect the functional capacity of our patients, nor the percentage of conclusive studies. This enables us to benefit from the information provided by the exercise stress modality, while reducing the risk of infection in healthcare personnel. Given the current pandemic situation, and in view of the results of our study, we strongly recommend the systematic incorporation of the surgical facemask in ESE protocols.

Rubén Cano Carrizal* and Carlos Casanova Rodríguez

Departamento de Cardiología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain

Decrease in the number of primary angioplasty procedures during the pandemic and its relationship with mortality from COVID-19. The role of competing risks

Descenso del número de angioplastias primarias durante la pandemia y su relación con la mortalidad por COVID-19. El papel de los riesgos competitivos

To the Editor,

In late 2019, a new disease called coronavirus disease 2019 (COVID-19) emerged in China. The infection quickly spread to the rest of the world and a pandemic ensued. Spain has been one of the hardest-hit countries in terms of the number of cases and deaths. The entire health system has been put under stress and there has been a shift in the care of many diseases, including cardiovascular disease. There have been significant drops in the number of admissions for acute myocardial infarction (AMI) not due to cardiovascular disease. There have been significant drops in the number of primary PCIs, given that an unknown number of patients without AMI event would have died as a result of COVID-19 without the opportunity for the event to occur. Our study aim was to establish whether there is a relationship between deaths from COVID-19 in each of the Spanish Autonomous Communities (ACs) and the number of primary percutaneous coronary interventions (PCIs) recorded during the pandemic. We conducted a sensitivity analysis to compare the relationship between the excess total mortality recorded and variation in primary PCIs, given that an unknown number of patients without a confirmed diagnosis of COVID-19 probably died from this disease but were not counted.

To this end, we obtained data on primary PCIs recently published by the working group on the Infarction Code of the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC), whose methodology has already been described. Briefly, primary PCIs performed in 73 Spanish interventional cardiology centers were compared in 2 time periods, the first before the start of the pandemic (February 24 to March 1, 2020) and the second after the start (March 16 to 22, 2020). These centers represent 90% of all Spanish centers performing this type of activity. We calculated the number of procedures per million population in each period and the difference between them to obtain the variation between the 2 periods (table 1).

Data on mortality and excess mortality due to COVID-19 were obtained from the records of the Ministry of Health, the Carlos III Health Institute (ISCIII), and the Mortality Monitoring System (MoMo) of the ISCIII. Linear and nonlinear models were used to determine the association between mortality due to COVID-19, excess of total mortality, and variation in the rate of primary PCI per million population. R² and significance levels were obtained for both models.

The comparison showed that between the 2 periods the number of primary PCIs dropped in most ACs. There were marked differences in mortality and excess mortality between the ACs (table 1). Neither of the models found a statistically significant association between mortality due to COVID 19 and variation in the primary PCI rate in the ACs (linear model: R² = 0.008; P = .918; nonlinear model: logarithmic R² = 0.068; P = .314; quadratic R² = 0.07; P = .954; cubic R² = 0.147; P = .744). The same strategy was used to determine associations between the excess of total mortality and variation in the PCI rate. Neither of the models found a statistically significant association between the variables (linear model: R² = 0.0059; P = .771; nonlinear model: logarithmic R² = 0.057; P = .356; quadratic R² = 0.007; P = .952; cubic R² = 0.021; P = .963).

Mortality and variation in primary PCIs were plotted in the ACs (figure 1A). Although the Community of Madrid and Castile-La Mancha had the most deaths, they had dropped in the primary PCIs rate that were similar to those in other ACs with lower mortality, such as Aragon or Cantabria, but lower than those in other ACs with much lower mortality, such as the Principality of Asturias or the Chartered Community of Navarre. No statistically significant association was found between the excess of total mortality and variation in the PCI rate (figure 1B).